The DOI matches its Crossref record; 38 of the 38 references it cites were found in a registry or an index.
Neoadjuvant Nivolumab plus Chemotherapy in Resectable Lung Cancer
Open accessAbstract
BACKGROUND: Neoadjuvant or adjuvant chemotherapy confers a modest benefit over surgery alone for resectable non-small-cell lung cancer (NSCLC). In early-phase trials, nivolumab-based neoadjuvant regimens have shown promising clinical activity; however, data from phase 3 trials are needed to confirm these findings. METHODS: In this open-label, phase 3 trial, we randomly assigned patients with stage IB to IIIA resectable NSCLC to receive nivolumab plus platinum-based chemotherapy or platinum-based chemotherapy alone, followed by resection. The primary end points were event-free survival and pathological complete response (0% viable tumor in resected lung and lymph nodes), both evaluated by blinded independent review. Overall survival was a key secondary end point. Safety was assessed in all treated patients. RESULTS: The median event-free survival was 31.6 months (95% confidence interval [CI], 30.2 to not reached) with nivolumab plus chemotherapy and 20.8 months (95% CI, 14.0 to 26.7) with chemotherapy alone (hazard ratio for disease progression, disease recurrence, or death, 0.63; 97.38% CI, 0.43 to 0.91; P = 0.005). The percentage of patients with a pathological complete response was 24.0% (95% CI, 18.0 to 31.0) and 2.2% (95% CI, 0.6 to 5.6), respectively (odds ratio, 13.94; 99% CI, 3.49 to 55.75; P<0.001). Results for event-free survival and pathological complete response across most subgroups favored nivolumab plus chemotherapy over chemotherapy alone. At the first prespecified interim analysis, the hazard ratio for death was 0.57 (99.67% CI, 0.30 to 1.07) and did not meet the criterion for significance. Of the patients who underwent randomization, 83.2% of those in the nivolumab-plus-chemotherapy group and 75.4% of those in the chemotherapy-alone group underwent surgery. Grade 3 or 4 treatment-related adverse events occurred in 33.5% of the patients in the nivolumab-plus-chemotherapy group and in 36.9% of those in the chemotherapy-alone group. CONCLUSIONS: In patients with resectable NSCLC, neoadjuvant nivolumab plus chemotherapy resulted in significantly longer event-free survival and a higher percentage of patients with a pathological complete response than chemotherapy alone. The addition of nivolumab to neoadjuvant chemotherapy did not increase the incidence of adverse events or impede the feasibility of surgery. (Funded by Bristol Myers Squibb; CheckMate 816 ClinicalTrials.gov number, NCT02998528.).
Overview
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
The cited source doesn’t support the claim as written.
In the citing paper
“Given the lack of successful trials in the perioperative space in HCC, no surrogate end point has been validated yet, as is the case for pCR in patients with NSCLC20,120 and breast cancer8.”
From Adjuvant and neoadjuvant immunotherapies in hepatocellular carcinoma (2024) · cites this paper as [20]
Checked by a reasoning model — may be wrong.
Experimental — accuracy not yet measuredThe cited source says what the claim attributes to it.
In the citing paper
“Since results from one of the first clinical trials of such a therapeutic approach in patients with NSCLC were reported in 2018 (ref. 19), the efficacy and safety of neoadjuvant ICIs have been firmly established in multiple tumour types, with FDA approvals for two indications (NSCLC20,120 and triple-negative breast cancer8).”
From Adjuvant and neoadjuvant immunotherapies in hepatocellular carcinoma (2024) · cites this paper as [20]
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
The National Comprehensive Cancer Network
McGivney, W. T. (1998) · Cancer · doi:10.1002/(sici)1097-0142(19980515)82:10+ · Cited by 16,760
Cortazar, P., Zhang, L., Untch, M., Mehta, K. M., Costantino, J. P., Wolmark, N., Bonnefoi, H. R., Cameron, D., Gianni, L., Valagussa, P., et al. (2014) · The Lancet · doi:10.1016/s0140-6736(13)62422-8 · Cited by 4,777
Fundamental Mechanisms of Immune Checkpoint Blockade Therapy
Wei, S. C., Duffy, C. R., & Allison, J. P. (2018) · Cancer Discovery · doi:10.1158/2159-8290.cd-18-0367 · Cited by 3,088
Lung adjuvant cisplatin evaluation: a pooled analysis by the LACE Collaborative Group.
Pignon, J.-P., Tribodet, H., Scagliotti, G. V., Douillard, J.-Y., Shepherd, F. A., Stephens, R. J., Dunant, A., Torri, V., Rosell, R., Seymour, L., et al. (2008) · Journal of Clinical Oncology · doi:10.1200/jco.2007.13.9030 · Cited by 2,642
Neoadjuvant PD-1 Blockade in Resectable Lung Cancer
Forde, P. M., Chaft, J. E., Smith, K. N., Anagnostou, V., Cottrell, T. R., Hellmann, M. D., Zahurak, M., Yang, S. C., Jones, D. R., Broderick, S., et al. (2018) · New England Journal of Medicine · doi:10.1056/nejmoa1716078 · Cited by 2,099
Self-citationOsimertinib in Resected EGFR -Mutated Non–Small-Cell Lung Cancer
Wu, Y.-L. L. C., Tsuboi, M., He, J., John, T., Grohé, C., Majem, M., Goldman, J. W., Лактионов, К. К., Kim, S., Kato, T., et al. (2020) · New England Journal of Medicine · doi:10.1056/nejmoa2027071 · Cited by 1,849
Felip, E., Altorki, N. K., Zhou, C., Csőszi, T., Vynnychenko, I. O., Goloborodko, O., Luft, A. V., Akopov, A. L., Martínez‐Martí, A., Kenmotsu, H., et al. (2021) · The Lancet · doi:10.1016/s0140-6736(21)02098-5 · Cited by 1,497
Self-citationLanger, C. J., Gadgeel, S. M., Borghaei, H., Papadimitrakopoulou, V. A., Patnaik, A., Powell, S. F., Gentzler, R. D., Martins, R. G., Stevenson, J. P., Jalal, S. I., et al. (2016) · The Lancet Oncology · doi:10.1016/s1470-2045(16)30498-3 · Cited by 1,404
Self-citationPaz-Ares, L., Ciuleanu, T.-E., Cobo, M., Schenker, M., Zurawski, B., Menezes, J., Richardet, E., Bennouna, J., Felip, E., Juan-Vidal, O., et al. (2021) · The Lancet Oncology · doi:10.1016/s1470-2045(20)30641-0 · Cited by 1,366
Self-citationNeoadjuvant checkpoint blockade for cancer immunotherapy
Topalian, S. L., Taube, J. M., & Pardoll, D. M. (2020) · Science · doi:10.1126/science.aax0182 · Cited by 1,001
Self-citation
Flagged first, then by citations
Cited by
Sorted by citations
Siegel, R. L., Miller, K. D., Wagle, N. S., & Jemal, A. (2023) · CA: A Cancer Journal for Clinicians · doi:10.3322/caac.21763 · Cited by 16,303
Siegel, R. L., Giaquinto, A. N., & Jemal, A. (2024) · CA: A Cancer Journal for Clinicians · doi:10.3322/caac.21820 · Cited by 9,533
Immune checkpoint therapy—current perspectives and future directions
Sharma, P., Goswami, S., Raychaudhuri, D., Siddiqui, B. A., Singh, P., Nagarajan, A., Liu, J., Subudhi, S. K., Poon, C., Gant, K. L., et al. (2023) · Cell · doi:10.1016/j.cell.2023.03.006 · Cited by 1,206
Perioperative Pembrolizumab for Early-Stage Non–Small-Cell Lung Cancer
Wakelee, H., Liberman, M., Kato, T., Tsuboi, M., Lee, S.-H., Gao, S., Chen, K.-N., Dooms, C., Majem, M., Eigendorff, E., et al. (2023) · New England Journal of Medicine · doi:10.1056/nejmoa2302983 · Cited by 1,180
Self-citationClinical implications of T cell exhaustion for cancer immunotherapy
Chow, A., Perica, K., Klebanoff, C. A., & Wolchok, J. D. (2022) · Nature Reviews Clinical Oncology · doi:10.1038/s41571-022-00689-z · Cited by 1,044
Neoadjuvant-adjuvant or adjuvant-only pembrolizumab in advanced melanoma
Patel, S. P., Othus, M., Chen, Y., Wright, G. P., Yost, K. J., Hyngstrom, J. R., Hu-Lieskovan, S., Lao, C. D., Fecher, L. A., Truong, T.-G., et al. (2023) · New England Journal of Medicine · doi:10.1056/nejmoa2211437 · Cited by 919
Perioperative Durvalumab for Resectable Non–Small-Cell Lung Cancer
Heymach, J. V., Harpole, D. H., Mitsudomi, T., Taube, J. M., Gálffy, G., Hochmair, M. J., Winder, T. L., Zukov, R. A., Garbaos, G., Gao, S., et al. (2023) · New England Journal of Medicine · doi:10.1056/nejmoa2304875 · Cited by 835
Self-citationCancer biomarkers: Emerging trends and clinical implications for personalized treatment
Passaro, A., Bakir, M. A., Hamilton, E. G., Diehn, M., André, F., Roy‐Chowdhuri, S., Mountzios, G., Wistuba, I. I., Swanton, C., & Peters, S. (2024) · Cell · doi:10.1016/j.cell.2024.02.041 · Cited by 726
Hendriks, L. E. L., Remón, J., Finn, C. F., Garassino, M. C., Heymach, J. V., Kerr, K. M., Tan, D. S. W., Veronesi, G., & Reck, M. (2024) · Nature Reviews Disease Primers · doi:10.1038/s41572-024-00551-9 · Cited by 690
Self-citationTherapy with oncolytic viruses: progress and challenges
Shalhout, S. Z., Miller, D. M., Emerick, K. S., & Kaufman, H. L. (2023) · Nature Reviews Clinical Oncology · doi:10.1038/s41571-022-00719-w · Cited by 618
Targeting immunogenic cell stress and death for cancer therapy
Galluzzi, L., Guilbaud, E., Schmidt, D. R., Kroemer, G., & Marincola, F. M. (2024) · Nature Reviews Drug Discovery · doi:10.1038/s41573-024-00920-9 · Cited by 638
Perioperative Nivolumab in Resectable Lung Cancer
Cascone, T., Awad, M. M., Spicer, J. D., He, J., Lü, S., Sepesi, B., Tanaka, F., Taube, J. M., Cornelissen, R., Havel, L., et al. (2024) · New England Journal of Medicine · doi:10.1056/nejmoa2311926 · Cited by 574
Self-citationPerioperative Nivolumab and Chemotherapy in Stage III Non–Small-Cell Lung Cancer
Provencio, M., Nadal, E., González-Larriba, J. L., Martínez‐Martí, A., Bernabé, R., Bosch‐Barrera, J., Casal‐Rubio, J., Calvo, V., Insa, A., Ponce, S., et al. (2023) · New England Journal of Medicine · doi:10.1056/nejmoa2215530 · Cited by 519
Self-citationNCCN Guidelines® Insights: Non–Small Cell Lung Cancer, Version 2.2023
Ettinger, D. S., Wood, D. E., Aisner, D. L., Akerley, W., Bauman, J. R., Bharat, A., Bruno, D. S., Chang, J. Y., Chirieac, L. R., DeCamp, M. M., et al. (2023) · Journal of the National Comprehensive Cancer Network · doi:10.6004/jnccn.2023.0020 · Cited by 504
Advances and challenges in the treatment of lung cancer
Li, Y., Yan, B., & He, S. (2023) · Biomedicine & Pharmacotherapy · doi:10.1016/j.biopha.2023.115891 · Cited by 492
Alectinib in Resected ALK -Positive Non–Small-Cell Lung Cancer
Wu, Y.-L. L. C., Dziadziuszko, R., Ahn, J. S., Barlési, F., Nishio, M., Lee, K. H., Lee, J. S., Zhong, W., Horinouchi, H., Mao, W., et al. (2024) · New England Journal of Medicine · doi:10.1056/nejmoa2310532 · Cited by 457
Perioperative Toripalimab Plus Chemotherapy for Patients With Resectable Non–Small Cell Lung Cancer
Lü, S., Zhang, W., Wu, L., Wang, W., Zhang, P., Neotorch Investigators, Fang, W., Xing, W., Chen, Q., Yang, L., et al. (2024) · JAMA · doi:10.1001/jama.2023.24735 · Cited by 405
Self-citationAdjuvant and neoadjuvant immunotherapies in hepatocellular carcinoma
Llovet, J. M., Pinyol, R., Yarchoan, M., Singal, A. G., Marron, T. U., Schwartz, M., Pikarsky, E., Kudo, M., & Finn, R. S. (2024) · Nature Reviews Clinical Oncology · doi:10.1038/s41571-024-00868-0 · Cited by 391
Luoma, A., Suo, S., Wang, Y., Gunasti, L., Porter, C. B. M., Nabilsi, N. H., Tadros, J., Ferretti, A. P., Liao, S., Gurer, C., et al. (2022) · Cell · doi:10.1016/j.cell.2022.06.018 · Cited by 398
Neoadjuvant Cemiplimab for Stage II to IV Cutaneous Squamous-Cell Carcinoma
Gross, N. D., Miller, D. M., Khushalani, N. I., Divi, V., Ruiz, E. S., Lipson, E. J., Meier, F. E., Su, Y. B., Swiecicki, P. L., Atlas, J., et al. (2022) · New England Journal of Medicine · doi:10.1056/nejmoa2209813 · Cited by 355
Self-citationAntigen presentation in cancer — mechanisms and clinical implications for immunotherapy
Yang, K., Halima, A., & Chan, T. A.-T. (2023) · Nature Reviews Clinical Oncology · doi:10.1038/s41571-023-00789-4 · Cited by 352
Spicer, J. D., Garassino, M. C., Wakelee, H. A., Liberman, M., Kato, T., Tsuboi, M., Lee, S., Chen, K., Dooms, C., Majem, M., et al. (2024) · The Lancet · doi:10.1016/s0140-6736(24)01756-2 · Cited by 328
Self-citationNeoadjuvant immune checkpoint blockade: A window of opportunity to advance cancer immunotherapy
Topalian, S. L., Forde, P. M., Emens, L. A., Yarchoan, M., Smith, K. N., & Pardoll, D. M. (2023) · Cancer Cell · doi:10.1016/j.ccell.2023.07.011 · Cited by 317
Self-citationOverall Survival with Neoadjuvant Nivolumab plus Chemotherapy in Lung Cancer
Forde, P. M., Spicer, J. D., Provencio, M., Mitsudomi, T., Awad, M. M., Wang, C., Lu, S., Felip, E., Swanson, S., Brahmer, J. R., et al. (2025) · New England Journal of Medicine · doi:10.1056/nejmoa2502931 · Cited by 273
Self-citationChaft, J. E., Öezkan, F., Kris, M. G., Bunn, P. A., Wistuba, I. I., Kwiatkowski, D. J., Owen, D. H., Tang, Y., Johnson, B. E., Lee, J. M., et al. (2022) · Nature Medicine · doi:10.1038/s41591-022-01962-5 · Cited by 255
Chang, J. Y., Lin, S. H., Dong, W., Liao, Z. X., Gandhi, S. J., Gay, C. M., Zhang, J. J., Chun, S. G., Elamin, Y. Y., Fossella, F. V., et al. (2023) · The Lancet · doi:10.1016/s0140-6736(23)01384-3 · Cited by 257
Neoadjuvant Chemoimmunotherapy for NSCLC
Sorin, M., Prosty, C. J., Ghaleb, L., Nie, K., Katergi, K., Shahzad, M. H., Dubé, L.-R., Atallah, A., Swaby, A. M., Dankner, M., et al. (2024) · JAMA Oncology · doi:10.1001/jamaoncol.2024.0057 · Cited by 247
Self-citationFekete, J. T., & Győrffy, B. (2025) · Journal of Medical Internet Research · doi:10.2196/64016 · Cited by 248
Mino-Kenudson, M. A., Schalper, K. A., Cooper, W. A., Đačić, S., Hirsch, F. R., Jain, D., López‐Ríos, F., Tsao, M., Yatabe, Y., Beasley, M. B., et al. (2022) · Journal of Thoracic Oncology · doi:10.1016/j.jtho.2022.09.109 · Cited by 235
Self-citationCascone, T., Leung, C. H., Weissferdt, A., Pataer, A., Carter, B. W., Godoy, M. C. B., Feldman, H. A., William, W. N., Xi, Y., Basu, S., et al. (2023) · Nature Medicine · doi:10.1038/s41591-022-02189-0 · Cited by 226
Squamous cell lung cancer: Current landscape and future therapeutic options
Lau, S. C. M., Pan, Y., Velcheti, V., & Wong, K. (2022) · Cancer Cell · doi:10.1016/j.ccell.2022.09.018 · Cited by 215
The changing treatment landscape of EGFR-mutant non-small-cell lung cancer
Zhou, F., Guo, H., Xia, Y., Le, X., Tan, D. S. W., Ramalingam, S. S., & Zhou, C. (2024) · Nature Reviews Clinical Oncology · doi:10.1038/s41571-024-00971-2 · Cited by 230
Update 2025: Management of Non‑Small-Cell Lung Cancer
Jeon, H., Wang, S., Song, J., Gill, H., & Cheng, H. (2025) · Lung · doi:10.1007/s00408-025-00801-x · Cited by 229
Mountzios, G., Remón, J., Hendriks, L. E. L., García‐Campelo, R., Rolfo, C. D., Schil, P. E. V., Forde, P. M., Besse, B., Subbiah, V., Reck, M., et al. (2023) · Nature Reviews Clinical Oncology · doi:10.1038/s41571-023-00794-7 · Cited by 212
Self-citationAssociation between pathologic response and survival after neoadjuvant therapy in lung cancer
Deutsch, J. S., Cimino-Mathews, A., Thompson, E., Provencio, M., Forde, P. M., Spicer, J., Girard, N., Wang, D., Anders, R. A., Gabrielson, E., et al. (2024) · Nature Medicine · doi:10.1038/s41591-023-02660-6 · Cited by 198
Self-citationAdvances in molecular pathology and therapy of non-small cell lung cancer
Huang, Q., Li, Y., Huang, Y., Wu, J., Bao, W., Xue, C., Li, X., Dong, S., Dong, Z., & Hu, S. (2025) · Signal Transduction and Targeted Therapy · doi:10.1038/s41392-025-02243-6 · Cited by 197
Sánchez‐Herrero, E., Serna‐Blasco, R., de Lope, L. R., González‐Rumayor, V., Romero, A., & Provencio, M. (2022) · Frontiers in Oncology · doi:10.3389/fonc.2022.943253 · Cited by 201
Self-citationLuke, J. J., Piha-Paul, S. A., Medina, T. M., Verschraegen, C. F., Varterasian, M. L., Brennan, A. M., Riese, R. J., Sokolovska, A., Strauss, J. F., Hava, D. L., et al. (2023) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-23-0118 · Cited by 188
Chemo-Immunotherapy: A New Trend in Cancer Treatment
Sordo‐Bahamonde, C., Lorenzo‐Herrero, S., González, A. P., Martínez‐Pérez, A., Rodrigo, J. P., Garcia-Pedrero, J. M., & Gonzalez, S. R. (2023) · Cancers · doi:10.3390/cancers15112912 · Cited by 192
Taifour, T., Attalla, S. S., Zuo, D., Gu, Y., Sanguin‐Gendreau, V., Proud, H., Solymoss, E., Bui, T., Kuasne, H., Papavasiliou, V., et al. (2023) · Immunity · doi:10.1016/j.immuni.2023.11.002 · Cited by 178
Spicer, J. D., Cascone, T., Wynes, M. W., Ahn, M., Đačić, S., Felip, E., Forde, P. M., Higgins, K. A., Kris, M. G., Mitsudomi, T., et al. (2024) · Journal of Thoracic Oncology · doi:10.1016/j.jtho.2024.06.010 · Cited by 179
Self-citationNiu, Z., Jin, R., Zhang, Y., & Li, H. (2022) · Signal Transduction and Targeted Therapy · doi:10.1038/s41392-022-01200-x · Cited by 185
NCCN Guidelines® Insights: Management of Immunotherapy-Related Toxicities, Version 2.2024
Thompson, J. A., Schneider, B. J., Brahmer, J. R., Zaid, M. I. A., Achufusi, A., Armand, P. A., Berkenstock, M., Bermas, B. L., Braaten, T. J., Budde, L. E., et al. (2024) · Journal of the National Comprehensive Cancer Network · doi:10.6004/jnccn.2024.0057 · Cited by 176
Self-citationMok, T. S. K., Nakagawa, K., Park, K., Ohe, Y., Girard, N., Kim, H. R., Wu, Y.-L. L. C., Gainor, J. F., Lee, S., Chiu, C., et al. (2024) · Journal of Clinical Oncology · doi:10.1200/jco.23.01017 · Cited by 171
Self-citationA single-cell atlas reveals immune heterogeneity in anti-PD-1-treated non-small cell lung cancer
Liu, Z., Yang, Z., Wu, J., Zhang, W., Sun, Y., Zhang, C., Bai, G., Li, Y., Fan, H., Chen, Y., et al. (2025) · Cell · doi:10.1016/j.cell.2025.03.018 · Cited by 184
Naidoo, J., Murphy, C., Atkins, M. B., Brahmer, J. R., Champiat, S., Feltquate, D., Krug, L. M., Moslehi, J. J., Pietanza, M. C., Riemer, J., et al. (2023) · Journal for ImmunoTherapy of Cancer · doi:10.1136/jitc-2022-006398 · Cited by 176
Self-citationZer, A., Ahn, M., Barlési, F., Bubendorf, L., Ruysscher, D. D., Garrido, P., Gautschi, O. P., Hendriks, L. E. L., Janne, P. A., Kerr, K. M., et al. (2025) · Annals of Oncology · doi:10.1016/j.annonc.2025.08.003 · Cited by 165
Self-citationSun, X., Liu, W., Sun, L., Mo, H., Feng, Y., Wu, X., Li, C., Chen, C., Li, J., Xin, Y., et al. (2022) · Journal for ImmunoTherapy of Cancer · doi:10.1136/jitc-2022-005531 · Cited by 164
Self-citationHuang, J. G., Osarogiagbon, R. U., Giroux, D. J., Nishimura, K. K., Billè, A., Cardillo, G., Detterbeck, F. C., Kernstine, K. H., Kim, H. K., Lievens, Y. N., et al. (2023) · Journal of Thoracic Oncology · doi:10.1016/j.jtho.2023.10.012 · Cited by 163
Shu, D. H., Ho, W. J., Kagohara, L. T., Girgis, A. A., Shin, S. M., Danilova, L., Lee, J. W., Sidiropoulos, D. N., Mitchell, S., Munjal, K., et al. (2024) · Nature Immunology · doi:10.1038/s41590-024-01992-w · Cited by 166
Self-citationManagement of locally advanced non‐small cell lung cancer: State of the art and future directions
Miao, D., Zhao, J., Han, Y., Zhou, J., Li, X., Zhang, T., Li, W., & Xia, Y. (2023) · 癌症：英文版 · doi:10.1002/cac2.12505 · Cited by 165
Recent advances in therapeutic strategies for non-small cell lung cancer
Su, P., Furuya, N., Asrar, A., Rolfo, C. D., Li, Z., Carbone, D. P., & He, K. (2025) · Journal of Hematology & Oncology · doi:10.1186/s13045-025-01679-1 · Cited by 164
Yue, D., Wang, W., Liu, H., Chen, Q., Chen, C., Liu, L., Zhang, P., Zhao, G., Yang, F., Han, G., et al. (2024) · The Lancet Respiratory Medicine · doi:10.1016/s2213-2600(24)00269-8 · Cited by 155
Self-citationNovel targets for immune-checkpoint inhibition in cancer
Borgeaud, M., Sandoval, J. L., Obéid, M., Banna, G. L., Michielin, O. A., Addeo, A., & Friedlaender, A. (2023) · Cancer Treatment Reviews · doi:10.1016/j.ctrv.2023.102614 · Cited by 150
Cascone, T., Kar, G., Spicer, J. D., García-Campelo, R., Weder, W., Daniel, D. B., Spigel, D. R., Hussein, M., Mazières, J., Oliveira, J., et al. (2023) · Cancer Discovery · doi:10.1158/2159-8290.cd-23-0436 · Cited by 142
Self-citationEnfield, K. S. S., Colliver, E., Lee, C., Magness, A., Moore, D. A., Sivakumar, M., Grigoriadis, K., Pich, O., Karasaki, T., Hobson, P. S., et al. (2024) · Cancer Discovery · doi:10.1158/2159-8290.cd-23-1380 · Cited by 151
Neoadjuvant nivolumab and relatlimab in locally advanced MMR-deficient colon cancer: a phase 2 trial
de Gooyer, P., Verschoor, Y. L., van den Dungen, L. D. W., Balduzzi, S., Marsman, H. A., Foppen, M. H. G., Grootscholten, C., Dokter, S., den Hartog, A. G., Verbeek, W. H. M., et al. (2024) · Nature Medicine · doi:10.1038/s41591-024-03250-w · Cited by 138
Deep Learning Model for Predicting Immunotherapy Response in Advanced Non−Small Cell Lung Cancer
Rakaee, M., Tafavvoghi, M., Ricciuti, B., Alessi, J. V., Cortellini, A., Citarella, F., Nibid, L., Perrone, G., Adib, E., Fulgenzi, C. A. M., et al. (2024) · JAMA Oncology · doi:10.1001/jamaoncol.2024.5356 · Cited by 143
Self-citationCurrent trends in sensitizing immune checkpoint inhibitors for cancer treatment
Wei, J., Li, W., Zhang, P., Guo, F., & Liu, M. (2024) · Molecular Cancer · doi:10.1186/s12943-024-02179-5 · Cited by 144
Kelly, R. J., Landon, B. V., Zaidi, A. H., Singh, D., Canzoniero, J. V., Balan, A., Hales, R. K., Voong, K. R., Battafarano, R. J., Jobe, B. A., et al. (2024) · Nature Medicine · doi:10.1038/s41591-024-02877-z · Cited by 133
Self-citationImmunosurveillance in clinical cancer management
Kroemer, G., Chan, T. A.-T., Eggermont, A. M. M., & Galluzzi, L. (2023) · CA A Cancer Journal for Clinicians · doi:10.3322/caac.21818 · Cited by 131
Immunogenicity of cell death and cancer immunotherapy with immune checkpoint inhibitors
Catanzaro, E., Beltrán‐Visiedo, M., Galluzzi, L., & Krysko, D. V. (2024) · Cellular and Molecular Immunology · doi:10.1038/s41423-024-01245-8 · Cited by 131
Lung Cancer Treatment Advances in 2022
Rous, F. A., Singhi, E. K., Sridhar, A., Faisal, M. S., & Desai, A. P. (2022) · Cancer Investigation · doi:10.1080/07357907.2022.2119479 · Cited by 126
Cancer metastasis: Molecular mechanisms and clinical perspectives
Khan, S. U., Fatima, K., Malik, F. A., Kalkavan, H., & Wani, A. (2023) · Pharmacology & Therapeutics · doi:10.1016/j.pharmthera.2023.108522 · Cited by 127
Sivapalan, L., Murray, J. C., Canzoniero, J. V., Landon, B., Jackson, J., Scott, S., Lam, V., Levy, B. P., Sausen, M., & Anagnostou, V. (2023) · Journal for ImmunoTherapy of Cancer · doi:10.1136/jitc-2022-005924 · Cited by 122
Self-citationWislez, M., Mazières, J., Lavolé, A., Zalcman, G., Carre, O., Egenod, T., Caliandro, R., Dubos‐Arvis, C., Jeannin, G., Molinier, O., et al. (2022) · Journal for ImmunoTherapy of Cancer · doi:10.1136/jitc-2022-005636 · Cited by 122
Stage III Non-Small-Cell Lung Cancer: An Overview of Treatment Options
Petrella, F., Rizzo, S., Attili, I., Passaro, A., Zilli, T., Martucci, F., Bonomo, L. D., Grande, F. D., Casiraghi, M., de Marinis, F., et al. (2023) · Current Oncology · doi:10.3390/curroncol30030239 · Cited by 112
Asleh, K., Dery, V., Taylor, C., Davey, M., Djeungoue‐Petga, M., & Ouellette, R. J. (2023) · Biomarker Research · doi:10.1186/s40364-023-00540-2 · Cited by 117
European Groundshot—addressing Europe's cancer research challenges: a Lancet Oncology Commission
Lawler, M., Davies, L., Oberst, S., Oliver, K. R., Eggermont, A. M. M., Schmutz, A., Vecchia, C. L., Allemani, C., Lievens, Y. N., Naredi, P. L. J., et al. (2022) · The Lancet Oncology · doi:10.1016/s1470-2045(22)00540-x · Cited by 116
Next-generation combination approaches for immune checkpoint therapy
Goswami, S., Pauken, K. E., Wang, L., & Sharma, P. (2024) · Nature Immunology · doi:10.1038/s41590-024-02015-4 · Cited by 114
Neoadjuvant Osimertinib for Resectable EGFR -Mutated Non–Small Cell Lung Cancer
He, J., Tsuboi, M., Weder, W., Chen, K.-N., Hochmair, M. J., Shih, J., Lee, S. Y., Lee, K., Nhung, N. V., Saeteng, S., et al. (2025) · Journal of Clinical Oncology · doi:10.1200/jco-25-00883 · Cited by 117
Self-citationLei, J., Zhao, J., Gong, L., Ni, Y., Zhou, Y., Tian, F., Liu, H., Gu, Z., Huang, L., Lü, Q., et al. (2023) · JAMA Oncology · doi:10.1001/jamaoncol.2023.2751 · Cited by 107
Self-citationGross, N. D., Miller, D. M., Khushalani, N. I., Divi, V., Ruiz, E. S., Lipson, E. J., Meier, F. E., Su, Y. B., Swiecicki, P. L., Atlas, J., et al. (2023) · The Lancet Oncology · doi:10.1016/s1470-2045(23)00459-x · Cited by 109
Self-citationSujit, S. J., Aminu, M., Karpinets, T. V., Chen, P., Saad, M. B., Salehjahromi, M., Boom, J. D., Qayati, M., George, J. M., Allen, H., et al. (2024) · Nature Communications · doi:10.1038/s41467-024-47512-0 · Cited by 109
Emerging evidence and treatment paradigm of non-small cell lung cancer
Liu, S. M., Zheng, M.-M., Pan, Y., Liu, S. M., Li, Y., & Wu, Y.-L. L. C. (2023) · Journal of Hematology & Oncology · doi:10.1186/s13045-023-01436-2 · Cited by 112
Huang, Y., Sun, J., Li, J., Zhu, D., Dong, M., Dou, S., Tang, Y., Shi, W., Sun, Q., Zhao, T., et al. (2022) · International Journal of Surgery · doi:10.1097/js9.0000000000000489 · Cited by 99
Huai, Q., Luo, C., Song, P., Bie, F., Bai, G., Li, Y., Liu, Y., Chen, X., Zhou, B., Sun, X., et al. (2023) · Cancer Science · doi:10.1111/cas.15964 · Cited by 109
Cortiula, F., Reymen, B. J. T., Peters, S., Mol, P. V., Wauters, E., Vansteenkiste, J., Ruysscher, D. D., & Hendriks, L. E. L. (2022) · Annals of Oncology · doi:10.1016/j.annonc.2022.06.013 · Cited by 100
Provencio, M., Nadal, E., Insa, A., Campelo, R. G., Casal, J., Dómine, M., Massutí, B., Majem, M., Rodríguez‐Abreu, D., Martínez‐Martí, A., et al. (2024) · The Lancet Oncology · doi:10.1016/s1470-2045(24)00498-4 · Cited by 99
Self-citationCui, X., Liu, S., He, S., Xu, J., & Sun, Y. (2025) · Molecular Cancer · doi:10.1186/s12943-025-02287-w · Cited by 105
Neoadjuvant Chemo-Immunotherapy for Early-Stage Non–Small Cell Lung Cancer
Banna, G. L., Hassan, M. A., Signori, A., Giunta, E. F., Maniam, A., Anpalakhan, S., Acharige, S. M., Ghose, A., & Addeo, A. (2024) · JAMA Network Open · doi:10.1001/jamanetworkopen.2024.6837 · Cited by 97
Tumour and microenvironment crosstalk in NSCLC progression and response to therapy
Rahal, Z., Darzi, R. E., Moghaddam, S. J., Cascone, T., & Kadara, H. N. (2025) · Nature Reviews Clinical Oncology · doi:10.1038/s41571-025-01021-1 · Cited by 105
Kidane, B., Bott, M. J., Spicer, J. D., Backhus, L. M., Chaft, J. E., Chudgar, N. P., Colson, Y. L., D’Amico, T. A., David, E. A., Lee, J. S.-J., et al. (2023) · Journal of Thoracic and Cardiovascular Surgery · doi:10.1016/j.jtcvs.2023.04.039 · Cited by 98
Self-citationRecurrence-Free Survival in Patients With Surgically Resected Non-Small Cell Lung Cancer
Rajaram, R., Huang, Q., Li, R. Z., Chandran, U., Zhang, Y., Amos, T. B., Wright, G. W. J., Ferko, N. C., & Kalsekar, I. D. (2023) · CHEST Journal · doi:10.1016/j.chest.2023.11.042 · Cited by 95
The Role of Immune Checkpoint Inhibitors in Cancer Therapy
Basudan, A. (2022) · Clinics and Practice · doi:10.3390/clinpract13010003 · Cited by 99
Immunotherapy resistance in non-small-cell lung cancer: From mechanism to clinical strategies
Zhou, S., & Yang, H. (2023) · Frontiers in Immunology · doi:10.3389/fimmu.2023.1129465 · Cited by 98
A patient-specific lung cancer assembloid model with heterogeneous tumor microenvironments
Zhang, Y., Hu, Q., Pei, Y., Luo, H., Wang, Z., Xu, X., Zhang, Q. H., Dai, J., Wang, Q., Fan, Z., et al. (2024) · Nature Communications · doi:10.1038/s41467-024-47737-z · Cited by 92
Elkrief, A., Pidgeon, R., Vareki, S. M., Messaoudene, M., Castagner, B., & Routy, B. (2025) · Nature Reviews Drug Discovery · doi:10.1038/s41573-025-01211-7 · Cited by 99
Hines, J. B., Cameron, R. B., Esposito, A., Kim, L., Porcu, L., Nuccio, A., Viscardi, G., Ferrara, R., Veronesi, G., Forde, P. M., et al. (2024) · Journal of Thoracic Oncology · doi:10.1016/j.jtho.2024.03.010 · Cited by 96
Self-citationSchüler, M., Cuppens, K., Plönes, T., Wiesweg, M., Pont, B. D., Hegedűs, B., Köster, J., Mairinger, F. D., Darwiche, K., Paschen, A., et al. (2024) · Nature Medicine · doi:10.1038/s41591-024-02965-0 · Cited by 91
Nair, R., Somasundaram, V., Kuriakose, A., Krishn, S. R., Raben, D., Salazar, R. L., & Nair, P. (2025) · Frontiers in Immunology · doi:10.3389/fimmu.2025.1548234 · Cited by 100
Immunotherapy in non-small cell lung cancer: Past, present, and future directions
Punekar, S. R., Shum, E., Grello, C., Lau, S. C. M., & Velcheti, V. (2022) · Frontiers in Oncology · doi:10.3389/fonc.2022.877594 · Cited by 89
Dykema, A. G., Zhang, J., Cheung, L. S., Connor, S. C., Zhang, B., Zeng, Z., Cherry, C., Li, T., Caushi, J. X., Nishimoto, M., et al. (2023) · Science Immunology · doi:10.1126/sciimmunol.adg1487 · Cited by 88
Self-citationNeoadjuvant Targeted Therapy in Resectable NSCLC: Current and Future Perspectives
Lee, J. M., McNamee, C., Toloza, E. M., Negrao, M. V., Lin, J., Shum, E., Cummings, A. L., Kris, M. G., Sepesi, B., Bāra, I., et al. (2023) · Journal of Thoracic Oncology · doi:10.1016/j.jtho.2023.07.006 · Cited by 89
Adjuvant PD-1 Blockade With Camrelizumab for Nasopharyngeal Carcinoma
Liang, Y., Liu, X., Shen, L., Hu, G., Zou, G., Zhang, N., Chen, C., Chen, X., Zhu, X., Yuan, Y., et al. (2025) · JAMA · doi:10.1001/jama.2025.1132 · Cited by 86
de Scordilli, M., Michelotti, A., Bertoli, E., Carlo, E. D., Conte, A. D., & Bearz, A. (2022) · International Journal of Molecular Sciences · doi:10.3390/ijms23137222 · Cited by 83
Fujiwara, Y., Horita, N., Adib, E., Zhou, S., Nassar, A. H., Asad, Z. U. A., Cortellini, A., & Naqash, A. R. (2023) · The Lancet Oncology · doi:10.1016/s1470-2045(23)00524-7 · Cited by 88
Anti-PD-1/PD-L1 therapy for colorectal cancer: Clinical implications and future considerations
Chen, X., Chen, L., Peng, X., Deng, L., Wang, Y., Li, J.-J., Guo, D., & Niu, X. (2023) · Translational Oncology · doi:10.1016/j.tranon.2023.101851 · Cited by 80
Zhou, Z., Ding, Z., Yuan, J., Shen, S., Jian, H., Tan, Q., Yang, Y., Chen, Z., Luo, Q., Cheng, X., et al. (2022) · Journal of Hematology & Oncology · doi:10.1186/s13045-022-01283-7 · Cited by 79
Self-citationTran, H. T., Heeke, S., Sujit, S. J., Vokes, N. I., Zhang, J., Aminu, M., Lam, V. K. L., Vaporciyan, A. A., Swisher, S. G., Godoy, M. C. B., et al. (2023) · Annals of Oncology · doi:10.1016/j.annonc.2023.11.008 · Cited by 78
Metadata
- Authors
- Forde, P. M., Spicer, J., Lu, S., Provencio, M., Mitsudomi, T., Awad, M. M., Felip, E., Broderick, S. R., Brahmer, J. R., Swanson, S. J., Kerr, K., Wang, C., Ciuleanu, T.-E., Saylors, G. B., Tanaka, F., Ito, H., Chen, K.-N., Liberman, M., Vokes, E. E., Taube, J. M., Dorange, C., Cai, J., Fiore, J., Jarkowski, A., Balli, D., Sausen, M., Pandya, D., Calvet, C. Y., & Girard, N.
- Affiliations
- Johns Hopkins University (US)
- From the Bloomberg–Kimmel Institute for Cancer Immunotherapy, Johns Hopkins Kimmel Cancer Center, Baltimore (P.M.F., S.R.B., J.R.B., J.M.T.); McGill University Health Center (J.S.), and Centre Hospitalier de l’Université de Montréal (M.L.) — both in Montreal; Shanghai Chest Hospital, School of Medicine, Shanghai Jiao Tong University, Shanghai (S.L.), Tianjin Lung Cancer Center, Tianjin Medical University Cancer Institute and Hospital, Tianjin (C.W.), and Peking University School of Oncology, Beijing Cancer Hospital, Beijing (K.-N.C.) — all in China; Hospital Universitario Puerta de Hierro, Madrid (M.P.); Kindai University Faculty of Medicine, Ohno-Higashi, Osaka-Sayama (T.M.), the University of Occupational and Environmental Health, Kitakyushu (F.T.), and Kanagawa Cancer Center, Yokohama (H.I.) — all in Japan; Dana–Farber Cancer Institute, Boston (M.M.A., S.J.S.); Vall d’Hebron Institute of Oncology, Barcelona (E.F.); Aberdeen Royal Infirmary, Aberdeen, United Kingdom (K.K.); Institutul Oncologic Prof. Dr....
- Venue
- New England Journal of Medicine
- Publisher
- Massachusetts Medical Society
- Published
- 2022-05-26
- Volume
- 386
- Issue
- 21
- Pages
- 1973-1985
- ISSN
- 0028-4793 (ISSN-L)
- 1533-4406
- PMC
- PMC9844511
- OpenAlex
- W4223502512
- Cited by
- 2,825
- References
- 38
- Citations by year
- 2026: 583 · 2025: 683 · 2024: 724 · 2023: 624 · 2022: 209
- FWCI
- 361.74
- Type
- journal article
- Language
- en
- Open access
- green
- www.ncbi.nlm.nih.gov
- Locations
- New England Journal of Medicine (publishedVersion)
- PubMed (publishedVersion)
- PubMed Central (acceptedVersion)
- Funders
- Bristol-Myers Squibb (N/A)
- Topics
- Health Sciences › Medicine › Pulmonary and Respiratory Medicine › Lung Cancer Diagnosis and Treatment
- Health Sciences › Medicine › Pulmonary and Respiratory Medicine › Lung Cancer Treatments and Mutations
- Health Sciences › Medicine › Oncology › Lung Cancer Research Studies
- Keywords
- nivolumab, neoadjuvant therapy, non-small cell lung cancer, resectable lung cancer, platinum-based chemotherapy, immune checkpoint inhibitors, event-free survival, pathological complete response, overall survival, treatment-related adverse events
- MeSH terms
- Antineoplastic Agents, Immunological, Ipilimumab, Nivolumab, Antineoplastic Agents, Antineoplastic Combined Chemotherapy Protocols, Carcinoma, Non-Small-Cell Lung, Humans, Lung Neoplasms, Neoplasm Recurrence, Local, Platinum Compounds, Neoadjuvant Therapy
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
